Arcadia Biosciences
RKDA
26 hedge funds and large institutions have $18.7M invested in Arcadia Biosciences in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 5 closing their positions.
3% less capital invested
Capital invested by funds: $19.4M → $18.7M (-$675K)
7% less funds holding
Funds holding: 28 → 26 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$44.3K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$23.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.4K |
| 4 |
Citigroup
New York
|
+$7.81K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$5.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$229K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$209K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$67.7K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$48K |
| 5 |
Millennium Management
New York
|
-$46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $2K | +$2.6K | +1 | New |
|
27
Morgan Stanley
New York
| $1K | -$2.6K | -1 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
PAM
29
Panagora Asset Management
Boston,
Massachusetts
| – | -$209K | -86 | Closed |
|
|
CS
30
Credit Suisse
Zurich,
Switzerland
| – | -$48K | -20 | Closed |
|
|
31
Millennium Management
New York
| – | -$46K | -19 | Closed |
|
32
SG Americas Securities
New York
| – | -$32K | -13 | Closed |
|
RKDA Hedge Fund Activity: Q4 2015 in Review
26 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2015, worth a combined $18.7M — down 3.5% from $19.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RKDA and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $44.3K. The largest seller was Goldman Sachs, cutting an estimated $229K.
- 26 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2015, down from 28 in Q3 2015.
- Funds reported $18.7M of Arcadia Biosciences stock for Q4 2015, down 3.5% quarter-over-quarter.
- 3 funds opened new Arcadia Biosciences positions in Q4 2015 and 5 closed out, a net change of -2 holders.
- The largest Arcadia Biosciences buyer in Q4 2015 was RhumbLine Advisers, an estimated $44.3K added.
- The largest Arcadia Biosciences seller in Q4 2015 was Goldman Sachs, an estimated $229K sold.
Based on aggregated 13F filings for Q4 2015.